Interferon-α plus ATRA Maintenance in High Risk AML

Refractory disease still remains the main cause of treatment failure in acute myeloid leukemia (AML). Life expectancy in patients with CR achieved after second line therapy for primary drug resistance, relapse or poor pretreatment is really short (~6 months). Any attempt to prolong remission duration in this high risk group patients should be of certain value. It’s a well established fact that INF-alfa and ATRA combination leads to a synergy in antiproliferative, antiangiogenic, antiviral and differentiating effects (Moore DM, 1994).